SpectrumX Announces Significant Updates at Knutsford Production Facility

• Critical upgrades allow the Company to produce SPC-069 drug substance for clinical trials
• Other new additions to the facility include dedicated quality control room, microbiology laboratory and office space

KNUTSFORD, England--(BUSINESS WIRE)--SpectrumX, a UK-based healthcare and pharmaceutical company, announced today that recent upgrades at its state-of-the-art production facility in Knutsford, Cheshire, will allow the Company to move forward for production of the pharmaceutical drug substance, SPC-069, for clinical trials.

Key to the recent updates is the completion of an ISO Class 8 Cleanroom, which includes a best-in-class air purification, ventilation, and pressure-cascade system to prevent air contaminants during manufacturing processes. Additional upgrades include a dedicated quality control room and a microbiology laboratory, which tests all raw materials, key manufacturing steps and finished cosmetic and biocide products.

Alongside the investment into the production facilities, the Company has created an open plan office space for the team, including a dedicated boardroom for sales, training and briefings. The investment into the facility provides a significant launchpad to start the clinical trial programme to progress the potential novel respiratory treatment, SPX-001, to market.

Ben Hibbert, Operations Director, says: “We are delighted our Knutsford facility now meets the standards required for the production of a pharmaceutical drug substance - in our case, SPC-069. To achieve this, we installed equipment across the facility and introduced new operating procedures. This is a significant step for the business as it allows us to kickstart our clinical trial programme. Thanks to the investment, we now have the right environment to create and distribute our full range of hypochlorous acid products, which we believe will be game-changers in the market.”

- ENDS -

About SpectrumX

SpectrumX is a UK-based healthcare and pharmaceuticals company focused on bringing to market a ground-breaking respiratory infection therapy and the roll-out of the most powerful hand sanitiser in the world to the NHS and other healthcare clients. Both products utilise unique patent pending HOCl formulations. HOCl is naturally occurring in human white blood cells and is a key contributor in the immune response to infection. It also has a direct killing activity against bacteria, viruses and fungi. It is well-tolerated in humans while also being the most effective known disinfectant when used on surfaces. For more on SpectrumX, visit www.spectrumx.com.

Available Media

Video: SpectrumX provides update on significant upgrades at Knutsford facility - YouTube